Skip to main content

Table 1 LINE-1 methylation level in colorectal cancer.

From: Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors

Clinical, pathologic or molecular feature Total N Mean Standard deviation P value^
All cases 869 61.4 9.6  
Sex     0.19
Men 394 (45%) 61.0 9.0  
Women 475 (55%) 61.8 10.1  
Age (years)     0.35
< 60 196 (23%) 60.5 10.5  
60-69 363 (42%) 61.7 8.7  
≥70 310 (36%) 61.5 9.9  
Body mass index (BMI, kg/m2)     0.96
< 30 667 (83%) 61.3 9.5  
≥30 141 (17%) 61.4 9.1  
Family history of colorectal cancer     0.005
(-) 657 (76%) 61.9 9.6  
(+) 212 (24%) 59.7 9.1  
Smoking status     0.99
Never 350 (41%) 61.4 10.1  
Past or current 508 (59%) 61.3 9.2  
Tumor location     0.024
Proximal colon (cecum to transverse) 370 (44%) 61.9 9.2  
Distal colon (splenic flexure to sigmoid) 274 (33%) 60.1 9.7  
Rectum 192 (23%) 62.3 9.4  
Disease stage     0.015
I 196 (25%) 61.5 9.2  
II 253 (33%) 62.5 9.2  
III 226 (29%) 60.1 9.5  
IV 103 (13%) 60.0 11.0  
Tumor grade     0.43
Low 777 (91%) 61.3 9.4  
High 79 (9.2%) 62.3 11.2  
Mucinous component     0.002
0% 554 (65%) 60.7 9.3  
1-49% 188 (22%) 61.3 10.0  
≥50% 115 (13%) 64.1 9.3  
Signet ring cell component     0.009
0% 796 (93%) 61.0 9.4  
1-49% 48 (5.6%) 63.5 10.8  
≥50% 14 (1.6%) 67.6 8.5  
Crohn's-like reaction     0.002
Absent/mild 684 (92%) 61.1 9.5  
Moderate/severe 62 (8.3%) 65.2 9.6  
Peritumoral lymphocytic reaction     0.018
Absent/mild 744 (89%) 60.9 9.4  
Moderate/severe 93 (11%) 63.6 10.3  
Tumor infiltrating lymphocytes (TIL)     0.043
Absent/mild 740 (89%) 60.9 9.5  
Moderate/severe 96 (11%) 63.2 10.2  
MSI status     < 0.0001
MSI-low/MSS 728 (85%) 60.7 9.5  
MSI-high 124 (15%) 64.7 8.9  
CIMP status     < 0.0001
CIMP-0 408 (47%) 60.2 9.8  
CIMP-low 333 (38%) 61.3 9.3  
CIMP-high 128 (15%) 65.1 8.3  
CIN status (in MSI-low/MSS cases)     0.0002
(-) 142 (25%) 63.7 9.6  
(+) 436 (75%) 60.3 9.0  
KRAS mutation     0.90
(-) 538 (63%) 61.3 9.6  
(+) 319 (37%) 61.2 9.4  
BRAF mutation     0.001
(-) 728 (87%) 60.8 9.3  
(+) 108 (13%) 64.2 10.2  
PIK3CA mutation     0.24
(-) 646 (85%) 61.1 9.7  
(+) 118 (15%) 62.2 9.3  
TP53 expression     0.096
(-) 488 (57%) 61.8 9.8  
(+) 371 (43%) 60.7 9.3  
CDKN1A (p21)     0.0002
Lost 682 (81%) 60.6 9.6  
Expressed 158 (19%) 63.7 9.0  
CTNNB1 (β-catenin) score*     0.47
0-2 (inactive) 482 (64%) 61.4 9.8  
3-5 (active) 273 (36%) 60.9 9.3  
PTGS2 (COX-2) expression     0.98
(-) 142 (16%) 61.3 11.2  
(+) 719 (84%) 61.3 9.2  
FASN expression     0.16
(-) 742 (88%) 61.1 9.7  
(+) 99 (12%) 62.4 8.7  
  1. ^ P value was calculated by t-test assuming unequal variances (for binary variables) or ANOVA (analysis of variance; for 3-category variables). * CTNNB1 score was calculated as previously described [24].
  2. There were cases with missing information in covariates. A p value for significance is adjusted to p = 0.0021 by Bonferroni correction for multiple hypothesis testing.
  3. CIMP, CpG island methylator phenotype; MSI, microsatellite instability; MSS, microsatellite stable.